Skip to main content
SpringerLink
Log in

Die zytoreduktive radikale Prostatektomie beim metastasierten Prostatakarzinom

Cytoreductive, radical prostatectomy in metastatic prostate cancer

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Die Resektion des Primarius bei Patienten mit primär metastasiertem Prostatakarzinom wird kontrovers diskutiert. Retrospektive Studien deuten auf einen Überlebensvorteil und auf eine Vermeidung von lokoregionären Sekundärkomplikationen hin, jedoch sind wegweisende Ergebnisse laufender multizentrischer prospektiver Studien derzeit noch ausstehend. Diese Übersichtsarbeit soll die Rationale hinter der zytoreduktiven Prostatektomie beleuchten sowie bisherige Ergebnisse klinischer Studien zusammenfassen.

Abstract

The resection of the primary tumor in patients with metastatic prostate cancer is controversially debated. Retrospective clinical studies indicate survival benefits and prevention of secondary, locoregional complications; however, results of ongoing multicenter prospective studies are still lacking. This review highlights the rationale behind the cytoreductive prostatectomy and summarizes current clinical study results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P (2006) Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol 24(5):396–402

    Article  PubMed  Google Scholar 

  2. Siddiqui MM, Rais-Bahrami S, Truong H et al (2013) Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol 64(5):713–719

    Article  PubMed  Google Scholar 

  3. Quinn M, Babb P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int 90(2):162–173

    Article  CAS  PubMed  Google Scholar 

  4. Gandaglia G, Bray F, Cooperberg MR et al (2016) Prostate cancer registries: current status and future directions. Eur Urol 69(6):998–1012

    Article  PubMed  Google Scholar 

  5. Spek A, Herlemann A, Gratzke C, Stief CG (2017) Radical prostatectomy as part of a multimodal concept for patients with prostate cancer and bone metastases at initial diagnosis. Urologe 56(5):595–598

    Article  CAS  PubMed  Google Scholar 

  6. Cornford P, Bellmunt J, Bolla M et al (2017) EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol 71(4):630–642

    Article  PubMed  Google Scholar 

  7. Attard G, Sydes MR, Mason MD et al (2014) Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol 66(5):799–802

    Article  CAS  PubMed  Google Scholar 

  8. James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024):1163–1177

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Fizazi K, Tran N, Fein L et al (2017) Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med 377(4):352–360

    Article  CAS  PubMed  Google Scholar 

  10. Ljungberg B, Bensalah K, Canfield S et al (2015) EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 67(5):913–924

    Article  PubMed  Google Scholar 

  11. Haffner MC, Mosbruger T, Esopi DM et al (2013) Tracking the clonal origin of lethal prostate cancer. J Clin Invest 123(11):4918–4922

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Faiena I, Singer EA, Pumill C, Kim IY (2014) Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (Review). Int J Oncol 45(6):2193–2198

    Article  PubMed  PubMed Central  Google Scholar 

  13. Patrikidou A, Brureau L, Casenave J et al (2015) Locoregional symptoms in patients with de novo metastatic prostate cancer: morbidity, management, and disease outcome. Urol Oncol 33(5):202e.9–202e.17

    Article  Google Scholar 

  14. Engel J, Bastian PJ, Baur H et al (2010) Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 57(5):754–761

    Article  PubMed  Google Scholar 

  15. Steuber T, Budaus L, Walz J et al (2011) Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 107(11):1755–1761

    Article  PubMed  Google Scholar 

  16. Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol 65(6):1058–1066

    Article  PubMed  Google Scholar 

  17. Gratzke C, Engel J, Stief CG (2014) Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry. Eur Urol 66(3):602–603

    Article  PubMed  Google Scholar 

  18. Antwi S, Everson TM (2014) Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol 38(4):435–441

    Article  PubMed  Google Scholar 

  19. Satkunasivam R, Kim AE, Desai M et al (2015) Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-Medicare Analysis. J Urol 194(2):378–385

    Article  PubMed  PubMed Central  Google Scholar 

  20. Leyh-Bannurah SR, Gazdovich S, Budaus L et al (2017) Local therapy improves survival in metastatic prostate cancer. Eur Urol 72(1):118–124

    Article  PubMed  Google Scholar 

  21. Steuber T, Berg KD, Roder MA et al (2017) Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study. Eur Urol Focus. https://doi.org/10.1016/j.euf.2017.06.016

    Google Scholar 

  22. Sooriakumaran P, Karnes J, Stief C et al (2016) A multi-institutional analysis of perioperative outcomes in 106 men who underwent radical prostatectomy for distant metastatic prostate cancer at presentation. Eur Urol 69(5):788–794

    Article  PubMed  Google Scholar 

  23. Satkunasivam R, Wallis CJ, Byrne J et al (2016) Perioperative outcomes following radical prostatectomy for patients with disseminated cancer: an analysis of the National Surgical Quality Improvement Program Database. Can Urol Assoc J 10(11):423–429

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urologische Klinik und Poliklinik, Campus Großhadern, Klinikum der Universität München, Ludwig-Maximilians Universität München, Marchioninistr. 15, 81377, München, Deutschland

    M. Chaloupka, A. Herlemann, A. Spek, C. Gratzke & C. Stief

Authors
  1. M. Chaloupka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Herlemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Spek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Gratzke
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Stief
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Chaloupka.

Ethics declarations

Interessenkonflikt

M. Chaloupka, A. Herlemann, A. Spek, C. Gratzke und C. Stief geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chaloupka, M., Herlemann, A., Spek, A. et al. Die zytoreduktive radikale Prostatektomie beim metastasierten Prostatakarzinom. Urologe 56, 1430–1434 (2017). https://doi.org/10.1007/s00120-017-0505-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-017-0505-2

Schlüsselwörter

Keywords

Search

Navigation